南方医科大学研究生导师介绍徐爱民

删除或更新信息，请邮件至freekaoyan#163.com(#换成@)

南方医科大学免费考研网/2012-11-10

姓名：徐爱民
性别：男
出生年月：1965.2
专业技术职务：教授
专业：病理生理学
导师层次：博士生导师
导师类别：学术型
最后学历：博士
工作单位：香港大学医学院HBHA中心
办公室电话：85228199754
电子邮件：amxu@hkucc.hku.hk

主要研究方向：研究方向:肥胖及糖尿病、心血管疾病的基础和应用研究
学术任职：1.Editor,BiochemicalJournal2.AcademicEditor,PLOSONE3.Boardmember,Journalof
Diabetes.4.JournalofObesity.AsaneditorforBiochemicalJournal(ajournalwith120yearsof
history),Iamhandling~25-30manuscriptsperyearrelatedtoobesity,energymetabolismand
signaltransduction.
2.Asaninvitedreviewerforover20journals,includingDiabetes,Am.J.ofPathology,Obesity,
ATVB,Clin.Chem,Am.J.Cardiology,Obesity,Molecularandcellularendocrinology,Physiology
Genomics,Toxicity,Journalofphysiology,InternationalJournalofBiochemistryandcellbiology,
AmJPhysiol,ClinScience,Nephrology,CellResearch,Proteomicsetc.Inthelasttwoyears,I
reviewed46manuscriptsforthesejournals.
3.AsaninvitedgrantreviewerforDiabetesUK,HongKongRGCandNewZealandHealth
ResearchGrant.
最具代表论文：1、TLR4mediatesobesity-inducednonalcoholicsteatohepatitisthroughactivationofX-boxbindingproteininmice，Gut,2012,Jan17.IF:10.614。
2、APPL1counteractsobesity-inducedvascularinsulinresistanceandendothelialdysfunctionbymodulatingtheendothelialproductionofnitricoxideandendothelin-1inmice，Diabetes,2011,60:3044-54，IF:8.889。
3、AdiponectinIsRequiredforPPARγ-MediatedImprovementofEndothelialFunctioninDiabeticMice，CellMetabolism,2011,16:101-15，IF:18.207。
4、AdiponectinPreventsDiabeticPrematureSenescenceofEndothelialProgenitorCellsandPromotesEndothelialRepairbySuppressingthep38MAPkinase/p16INK4ASignalingPathway，Diabetes,2010,59:2949-59，IF:8.889。
5、APPL1PotentiatesInsulin-mediatedInhibitionofHepaticGlucoseProductionandAlleviatesDiabetesviaAktActivationinMice，CellMetabolism,2009,9:417-27，IF:18.207。
最具代表学术专著：A:PatentAwardedasaprimaryinventor(3)
1.Phosphoproteintargetforinsulinandinsulinantagonists.(USpatentnumber:US6,884,575)
2.Adiponectinandusesthereof.(USpatentNumber:7,365,170)
3.Lipocalin-2asadiagnosticmarkerandtherapeutictarget.USpatentNo:7,645,616.
B:Patentinapplicationasaninventor(5)
1.FALPproteins.(InternationalApplicationNo:PCT/NZ03/00039,US20050074756,USutility
applicationfiled03/03/2003)
2..PeptideswithAnti-ObesityActivityandOtherRelatedUses,USpatentapplicationNo:
20070275872
3.MethodforDecreasingBloodGlucoseandImprovingGlucoseToleranceUsingAngiopoietin-
Protein4.USPatentApplicationNumber:20080095782.
4.Lipocalin-2asaprognosticanddiagnosticmarkerforheartandstrokerisks.USpatentapplication
20090274709
主要获奖情况：1.OutstandingYoungResearcher,UniversityofHongKong,2005-6
2.BestdoctoralThesis,UniversityofAuckland,2000
在研课题：1、TheLiver-derivedHormoneFGF21asaNovelRegulatorofVascularFunction:MolecularBasisandPhysiologicalImplications(784111M)，GeneralResearchFund，2012~2014，HK$1,437,500.
2、APPL2asaNegativeRegulatorofInsulinSensitivityandGlucoseUptakeinSkeletalMuscle:ANovelPathwayLeadingtoInsulinResistance?(783010M)，GeneralResearchFund，2011~2013，HK$1,380,000。
本人目前可支配总经费：HK$2,817,500。
本人从事的主要研究方向及其特点和意义、开展新医疗、新技术等情况、国内所处的学术地位徐爱民教授是一位著名的糖尿病和心血管疾病专家，在肥胖相关的糖尿病和心血管疾病基础和应用研究方面具有渊博的知识、丰富的研究经验，在国际著名刊物上发表了多篇科研论文，并有多年指导博士研究生的实践经验。
Myresearchisdedicatedtodelineatethemolecularbasisthatlinksobesitywithdiabetesand
cardiovasculardisease,withparticularfocusesonadipokinesreleasedfromfattissue.Ourteamisone
ofthewordleadinggroupsinthefieldofadiponectin,amajorfat-derivedinsulin-sensitizing
adipokinewithanti-diabetic,anti-atheroscleroticandanti-inflammatoryproperties.Ourresearchwork
contributedsubstantiallytotheunderstandingofthemolecularstructure,signalingpathwaysand
physiologicalfunctionsofadiponectin.Severalkeyfindingsreportedfromourlaboratory,including
theposttranslationalmodificationinregulatingoligomerizationandsecretionofadiponectin,the
sexualdimorphismofadiponectin,andtheprotectiveroleofadiponectinagainstobesity-relatedfatty
liverandbreastcancer,havebeenwidelyacceptedandextensivelycitedinthisfield.Inthepastsix
year,ourgroup,incollaborationwithseveraloverseasinstitutes,haspublished42papersrelatedto
adiponectinintop-rankedjournals,includingCellMetabolism,JClinInvest,PNAS,Gastroenterology,
Hepatology,Diabetes,CancerResearch,AmJPathol,andJBC(6)etc(seethepublicationlistbelow).
Wehaveprovidedtheresearchtoolsgeneratedinourlaboratory(antibodies,celllines,immunoassays,
virusesandrecombinantadiponectinetc)toover30localandoverseaslaboratoriestosupporttheir
research.Ihavebeeninvitedtocontributereviewpapersbyseveralprestigiousjournals,including
BiochemicalJ,ClinScience,andExpertReviewinEndocrinology&Metabolismetc.
Inadditiontoadiponectin,ourlaboratoryhasidentifiedseveralothernewadipokines,
includingadipocytefattyacidbindingprotein(A-FABP),FGF21,Angptl4andlipocalin-2.Wehave
comprehensivelyinvestigatedthephysiologicalfunctionsoftheseadipokinesinanimalmodelsand
theclinicalrelevanceinhumans.Thediscoveryofthesenewadipokinesbyourgroupuncoversnovel
molecularlinksbetweenobesityanditsmetabolicandcardiovascularcomplications,andprovidesnewtargetsfortherapeuticinterventionandearlydiagnosis.Thispartofworkledto15publicationsintop
journals,includingCirculation,Diabetes,DiabetesCare(2),EuropeanHeartJ,Hepatology,Clin
Chemistry(2),PNASandATVBetc.Inaddition,wearealsousingthetransgenesisapproachesto
understandtheroleandmechanismsofadiposetissueinflammationinthepathogenesisofobesity-
inducedinsulinresistanceandvasculardysfunction.Wehavegeneratedseveralunique
transgenic/knockoutmousemodelswithfattissue-selectiveinactivationofseveralkeyinflammatory
pathways,whicharecurrentlyundercomprehensivephenotypiccharacterization.